Brokerage Firm Rating Update on Impax Laboratories (IPXL)

Impax Laboratories (IPXL) : The consensus on Impax Laboratories (IPXL) based on 9 analyst recommendation on the company stock is 2.33, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 6 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Impax Laboratories (IPXL) : The most positive equity analysts on Impax Laboratories (IPXL) expects the shares to touch $32, whereas, the least positive believes that the stock will trade at $24 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $28 with an expected fluctuation of $3.16 from the mean.


Company shares have received an average consensus rating of Hold for the current week Also, Equity analysts at the Brokerage firm Northland Securities upgrades its rating on Impax Laboratories (NASDAQ:IPXL). The rating major has initiated the coverage with outperform rating on the shares. Earlier, the shares were rated a Market Perform by the brokerage firm. The rating by the firm was issued on August 15, 2016.

Impax Laboratories (NASDAQ:IPXL): The stock opened at $24.22 and touched an intraday high of $24.56 on Wednesday. During the day, the stock corrected to an intraday low of $24.22, however, the bulls stepped in and pushed the price higher to close in the green at $24.47 with a gain of 0.95% for the day. The total traded volume for the day was 714,678. The stock had closed at $24.24 in the previous trading session.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.